Shaken MorphoSys ‘Assessing Options’ After Losing US Darzalex Patent Ruling

But German Biotech says court summary judgement will have no bearing on MorphoSys's own CD38 antibody MOR202.

WoodenFigure
MorphoSys Hit By Patent Lawsuit Ruling Over Blood Cancer Drug • Source: Shutterstock

MorphoSys AG said it was "disappointed" about a US court ruling against the German biotech in its three-year patent dispute with Danish biotech Genmab AS and pharma giant Johnson & Johnson over blood cancer blockbuster Darzalex (daratumumab). The ruling has blocked the start of a jury trial.

The complaint, filed in 2016 by MorphoSys with the US District Court of Delaware, alleges that Darzalex, an antibody-based biologic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Legal & IP

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.